雲南白藥(000538.SZ)：擬對萬隆控股進行強制性全面要約收購
格隆匯11月4日丨雲南白藥(000538.SZ)公佈，為貫徹落實《“健康中國2030”規劃綱要》的總體部署，加快推動中國醫藥健康企業走出去步伐，提升公司的業務國際化水平，雲南白藥二級全資子公司雲南白藥集團(海南)有限公司(“白藥海南”)已在香港設立三級全資子公司雲白藥香港有限公司(“白藥香港”)作為雲南白藥提升國際化業務水平的重要載體。此次交易將由白藥香港作為要約人，對萬隆控股集團有限公司(“萬隆控股”或“標的公司”)除要約人及其一致行動人士外所有股東(“獨立股東”)持有的全部已發行股份發出強制性全面現金要約。
此次交易前，雲南白藥持有萬隆控股1,908,025,360股股份，佔万隆控股已發行總股本約29.59%。2021年9月9日，新華都集團(香港)投資有限公司(“新華都香港”)以0.285港元/股的價格在香港公開市場收購了萬隆控股5600萬股股票，佔万隆控股已發行股本約0.87%。
根據香港證券與期貨事務監察委員會頒佈的《公司收購、合並及股份購回守則》之規定，雲南白藥與新華都香港被視為一致行動人士，合計持有萬隆控股1,964,025,360股股份，達到萬隆控股已發行股本的30.46%，須向萬隆控股的獨立股東持有的全部已發行股份提出強制性全面現金要約。
為進一步強化與萬隆控股的戰略協同，雲南白藥擬以白藥香港作為要約人對萬隆控股進行強制性全面要約收購。
按要約價每股要約股份0.285港元，並以萬隆控股已發行股本自對外披露3.5公吿之日起至要約截止日期止無任何變動為基礎，假設要約獲全面接納，此次交易對價約12.78億港元。
雲南白藥擬通過此次要約收購萬隆控股股權，進一步強化雙方的戰略協同，提升雲南白藥的業務國際化水平。藉助萬隆控股在產品貿易和銷售渠道方面的優勢，雙方將能夠實現互利共贏的業務發展機遇，預計本次投資未來能夠為雲南白藥實現良好的投資回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
